How to Apply for Embryonic Stem Cell Research Protocol Approval

Embryonic Stem Cell Research Oversight How to Apply for Embryonic Stem Cell Research Protocol Approval
Purple hero (default)
Embryonic Stem Cell Research Oversight How to Apply for Embryonic Stem Cell Research Protocol Approval

Researchers looking to conduct experiments involving the use of human embryonic stem cells or human pluripotent stem cells at NYU School of Medicine submit a research protocol to our embryonic stem cell research oversight (ESCRO) committee. To apply, all principal investigators and study personnel first complete a required training and agree to our policy.

If you are a researcher initiating a study, complete the ESCRO application form and submit it to escro@nyumc.org. Provide a study number, if one has been assigned, and attach a detailed description of your proposed research protocol.

If your study involves the use of cryopreserved embryos, submit the cryopreserved embryo disposition form, as well. If your research is part of an Institutional Review Board–approved study, please include a copy of that protocol.

Annual Progress Report

Research protocols involving the use of human embryonic stem cells or human pluripotent stem cells must be approved annually by our oversight committee. To apply for renewal of your study, submit an annual progress report, detailing any modifications to the experimental protocols, to escro@nyumc.org.

Send the report four to six weeks prior to your study’s expiration date to allow sufficient time for review.

Annual Progress Report Template

Certain elements must be included in your annual progress report to ensure effective review. We suggest you begin by using the following format:

  • date of progress report
  • name of principal investigator
  • name of department
  • study number
  • study title
  • contact information

Be sure to describe the following in your report:

  • Were there any modifications to your approved research protocol within the past 12 months? Please provide information, if so.
  • Detail any changes in experimental protocols using human embryonic stem cells or derivatives, human gametes, or embryos.
  • Detail any changes in research personnel, including postdoctoral fellows and graduate students.
  • Detail any requests for additional types or sources of human embryonic stem cell lines or other human biological materials.
  • Detail any changes in the procurement of human embryos or gametes.
  • Detail any changes in laboratory location.
  • List all human embryonic stem cell lines or genetically modified human embryonic stem cell lines that you have received within the past 12 months in connection with this study, and confirm the total quantity received.
  • List any other human embryonic stem cell lines or genetically modified human embryonic stem cell lines that you anticipate using within the next 12 months and their sources.